Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001688 | 1.00 | BDKRB1 (0.43) | BDKRB1TDP1MMP9AIMP2MEN1 | |
| SCHEMBL5002159 | 0.94 | BDKRB1 (0.41) | BDKRB1AIMP2MEN1KMT2A | |
| SCHEMBL5001845 | 0.94 | BDKRB1 (0.41) | BDKRB1AIMP2MEN1KMT2A | |
| SCHEMBL5001844 | 0.94 | BDKRB1 (0.41) | BDKRB1AIMP2MEN1KMT2A | |
| SCHEMBL5007692 | 0.88 | BDKRB1 (0.37) | BDKRB1 | |
| SCHEMBL5001778 | 0.85 | BDKRB1 (0.45) | BDKRB1TDP1MMP9ITGB3ITGA2B | |
| SCHEMBL5001780 | 0.85 | BDKRB1 (0.45) | BDKRB1TDP1MMP9ITGB3ITGA2B | |
| SCHEMBL5001659 | 0.85 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5001661 | 0.85 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL14029683 | 0.85 | BDKRB1 (0.44) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | BDKRB1 1/4885TDP1 3759/4885MMP9 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.